

Women have greater atheroma regression with statins

8 October 2014



regression than men among those with on-treatment LDL-C levels

(HealthDay)—For patients with coronary atheroma, high-intensity statin treatment is associated with greater regression in women than men, according to a study published online Sept. 17 in *JACC:* Cardiovascular Imaging.

Rishi Puri, M.B.B.S., from the Cleveland Clinic in Ohio, and colleagues examined sex-related differences in coronary atheroma regression after high-intensity statin <u>treatment</u>. Participants (765 men and 274 women) were treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months.

The researchers found that women were older and more likely to have hypertension; diabetes; and higher low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and Creactive protein (CRP) levels than men. Compared with men, at follow-up women had higher HDL-C (P < 0.001) and CRP (P < 0.001) but similar LDL-C (P = 0.46) levels. Women had lower baseline percent atheroma volume (PAV) and total atheroma volume (TAV) than men, but after treatment they demonstrated greater PAV regression (P = 0.03) and TAV regression (P = 0.11). Female sex was independently associated with PAV regression on multivariate analysis (P = 0.01), and there was a sex-treatment interaction (P = 0.036). Women achieved greater PAV and TAV



APA citation: Women have greater atheroma regression with statins (2014, October 8) retrieved 1 May 2021 from https://medicalxpress.com/news/2014-10-women-greater-atheroma-regression-statins.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.